1. [Argentinean consensus guidelines on the use of monoclonal antibodies in patients with migraine].
- Author
-
Doctorovich ED, Martín-Bertuzzi F, Goicochea MT, Miranda S, Figuerola ML, Schubaroff PA, Buonanotte F, Rocchi V, Rua I, Bruera OC, Giglio J, De Paz JJ, Pelli-Noble R, Arago L, Burgos M, Ayala LS, Davidow L, and Bonamico L
- Subjects
- Argentina, Humans, Practice Guidelines as Topic, Antibodies, Monoclonal therapeutic use, Migraine Disorders drug therapy
- Abstract
Introduction: Migraine is a very prevalent disorder that is estimated to affect about 15% of adult subjects. Recently, the efficacy and safety of monoclonal antibodies that act on the calcitonin gene-related peptide pathway (MA-CGRP) has been evaluated in migraine. Several groups around the world have developed consensus guidelines about the use of monoclonal antibodies, however, in some regions is difficult to extrapolate the recommendations., Aim: To provide recommendations for the use of MA-CGRP in migraine in Argentina., Development: A group of neurology experts from Argentina, by using the online surveys methodology as well as face to face meetings developed the intended consensus for the use of MA-CGRP in migraine in Argentina. Recommendations were established based on published evidence and the expert opinion. Recommendations focused on how, when, treatment duration and patients follow up., Conclusion: The recommendations of this consensus guidelines attempt to optimize the use of MA-CGRP in migraine in Argentina.
- Published
- 2020
- Full Text
- View/download PDF